Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408394 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam
A Phase 1 study of Healthy, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01408394 is a Phase 1 study of Healthy that has completed, run by Emalex Biosciences. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01408394, a Phase 1 study of Healthy, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Ecopipam hydrochloride (HCl) is an investigational drug being studied for several possible diseases. To date, all clinical studies have been done using the ecopipam immediate release (IR) tablet. However, a controlled release (CR) capsule formulation of ecopipam has been produced that may be able to improve its effectiveness and reduce its side effects. The main purpose of this study is to evaluate the safety and tolerability of ecopipam CR capsules when given as single oral dose in healthy volunteers.
Conditions Studied
Interventions
- DRUG Ecopipam immediate release form
- DRUG 90 mg controlled release form
- DRUG 180 mg controlled release form
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408394
The ClinicalTrials.gov registry entry for NCT01408394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Ecopipam immediate release form is the first listed.
NCT01408394 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01408394 about?
NCT01408394 is a clinical study titled "Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam". Ecopipam hydrochloride (HCl) is an investigational drug being studied for several possible diseases. To date, all clinical studies have been done using the ecopipam immediate release (IR) tablet. However, a controlled release (CR) capsule formulation of ecopipam has been produced that may be able to...
What is the current status of trial NCT01408394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-08. Estimated completion is 2012-05.
What conditions does trial NCT01408394 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01408394?
The interventions under investigation include: Ecopipam immediate release form (DRUG), 90 mg controlled release form (DRUG), 180 mg controlled release form (DRUG).
Who is sponsoring clinical trial NCT01408394?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408394 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.